Showing results (171-180 of 199) with videos related to

Sort By:
Pageof 20
The Lancet. Haematology|October 1, 2019
Obstetric and maternal outcomes in patients diagnosed with Hodgkin lymphoma during pregnancy: a multicentre, retrospective, cohort studyCharlotte Maggen, Daan Dierickx, Pieternella Lugtenburg, et al.
Bone Marrow Transplantation|February 22, 2018
Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow TransplantationIrit Avivi, Ariane Boumendil, Hervé Finel, et al.
Blood Advances|May 20, 2024
Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed/refractory multiple myelomaShlomit Kfir-Erenfeld, Nathalie Asherie, Eyal Lebel, et al.
Leukemia Research|September 30, 2023
Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromesTamanna Haque, Felix López Cadenas, Blanca Xicoy, et al.
British Journal of Haematology|September 30, 2021
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphomaMax S Topp, Tom van Meerten, Roch Houot, et al.
Transplantation and Cellular Therapy|October 13, 2024
Addition of Nivolumab Tailored by Expansion of CAR-T Cells in Patients with Stable/Progressive Large B Cell Lymphoma at Lymphodepletion-A Phase 2, Prospective Interventional StudyRon Ram, Odelia Amit, Chava Perry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2013
Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patientsJacalyn Rosenblatt, Irit Avivi, Baldev Vasir, et al.
British Journal of Haematology|September 30, 2016
Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control studyArtur Jurczyszyn, Hareth Nahi, Irit Avivi, et al.
The Lancet. Haematology|July 23, 2019
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trialSaad Zafar Usmani, Fredrik Schjesvold, Albert Oriol, et al.
The New England Journal of Medicine|January 8, 2025
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple MyelomaYael C Cohen, Hila Magen, Moshe Gatt, et al.
Pageof 20